---
title: "Sunshine Pharmaceutical climbs 4% after reporting 1H results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296554561.md"
description: "Sunshine Pharmaceutical climbed 3.6% in Hong Kong after reporting 1H revenue growth and new drug approvals."
datetime: "2026-08-21T01:38:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296554561.md)
  - [en](https://longbridge.com/en/news/296554561.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296554561.md)
generator: "portal-rs"
---

# Sunshine Pharmaceutical climbs 4% after reporting 1H results

Sunshine Pharmaceutical (1530.HK) climbed **3.6%** to HK$**17.10** in Hong Kong trading on Friday.

The move followed the company's first-half 2026 results. Revenue rose **3.9%** to **RMB 4.53 billion**, while net profit fell **15.6%** to **RMB 1.15 billion**. The company noted progress on its innovation pipeline, with biosimilar Yisaipu and a new indication winning regulatory approval. Its R&D staff expanded to roughly **840**, and management said it will continue commercialization and drug-development partnerships in the second half.

### Related Stocks

- [01530.HK](https://longbridge.com/en/quote/01530.HK.md)

## Related News & Research

- [Frogbet Launches Crypto Casino With 70 In- House Original Games, Instant Withdrawals and a $10,000 Weekly Race](https://longbridge.com/en/news/297616927.md)
- [AstraZeneca-Hutchmed drug combination shows promise in advanced lung cancer study](https://longbridge.com/en/news/297608177.md)
- [Lee’s Pharmaceutical FY26 H1 profit attributable to owners climbs 41.4% to HK$ 95.01 million; revenue rises 14.6% to HK$ 796.57 million](https://longbridge.com/en/news/297495152.md)
- [Luye Pharma Delivers Higher H1 Profit Despite Revenue Decline](https://longbridge.com/en/news/297428133.md)
- [Ocumension completes first patient enrollment in Phase III China trial of dry eye drug OT-202](https://longbridge.com/en/news/297500609.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**